46 completed, 17 terminated, 8 active not recruiting, 6 withdrawn. 47 Phase 2, 43 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Recurrent Plasma Cell Myeloma: new trials by email Literature Review of Recurrent Plasma Cell Myeloma trials Research Report on Recurrent Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Carfilzomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 8 | 2022-12-08 | 2026-09-15 |
| Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Actinium Ac 225-DOTA-Daratumumab, Daratumumab, Indium In 111-DOTA-Daratumumab - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2022-11-22 | 2025-10-29 |
| Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma Tocilizumab, Venetoclax - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Active not recruiting | Emory University | 7 | 2022-10-19 | 2026-02-17 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Not applicable | Recruiting | Roswell Park Cancer Institute | 175 | 2022-06-28 | 2025-12-01 |
| Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma Autologous MUC1-activated T-cells, Cyclophosphamide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 5 | 2022-06-20 | 2026-04-03 |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Carfilzomib, Isatuximab, Pomalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 5 | 2022-06-14 | 2026-07-02 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Pembrolizumab - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Terminated | Alfred Chung, MD | 3 | 2022-05-03 | 2025-01-15 |
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Abdullah Khan | 1 | 2021-09-27 | 2024-06-06 |
| Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers Questionnaire Administration - Advanced Malignant Solid Neoplasm, Caregiver | Active not recruiting | M.D. Anderson Cancer Center | 192 | 2021-06-22 | 2026-08-06 | |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 5 | 2021-06-03 | 2025-05-18 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab - Recurrent Plasma Cell Myeloma | Phase 2 | Terminated | Srinivas Devarakonda | 1 | 2020-12-22 | 2023-09-28 |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab Azacitidine, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of California, San Francisco | 5 | 2020-11-30 | 2024-04-30 |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Dexamethasone, Leflunomide, Pomalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Recruiting | City of Hope Medical Center | 29 | 2020-11-24 | 2026-05-29 |
| Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Daratumumab, Dexamethasone, Pomalidomide - Recurrent Plasma Cell Myeloma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-08-07 | 2022-06-15 | |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Completed | University of California, San Francisco | 23 | 2020-04-16 | 2023-08-21 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 |
Showing 20 of 82. Sign in to see all of them.
Multiple Myeloma (82) · Hodgkin Disease (15) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Lymphoma, Non-Hodgkin (10) · Lymphoma, Mantle-Cell (8) · Lymphoma, Large B-Cell, Diffuse (7) · Myeloproliferative Disorders (6) · Leukemia, Plasma Cell (5) · Waldenstrom Macroglobulinemia (5) · Chromosome 17 deletion (4) · Hematologic Neoplasms (4)
Blood Protein Disorders (82) · Cardiovascular Diseases (82) · Hemic and Lymphatic Diseases (82) · Hemorrhagic Disorders (82) · Hemostatic Disorders (82) · Immune System Diseases (82) · Immunoproliferative Disorders (82) · Neoplasms by Histologic Type (82) · Paraproteinemias (82) · Vascular Diseases (82) · Hematologic Diseases (81) · Lymphoproliferative Disorders (81) · Neoplasms (81) · Neoplasms, Plasma Cell (80) · Leukemia (20)
Calcium Dobesilate (32) · Dexamethasone (32) · auricularum (28) · dexamethasone 21-phosphate (28) · dexamethasone acetate (28) · Cyclophosphamide (19) · daratumumab (12) · Mycophenolic Acid (11) · ixazomib (11) · Bortezomib (10) · Melphalan (10) · fludarabine phosphate (10) · Lenalidomide (9) · Peripheral Blood Stem Cell Transplantation (9) · Tacrolimus (9)
Mayo Clinic (16) · M.D. Anderson Cancer Center (11) · Fred Hutchinson Cancer Center (10) · City of Hope Medical Center (9) · National Cancer Institute (NCI) (6) · Emory University (4) · OHSU Knight Cancer Institute (4) · Academic and Community Cancer Research United (2) · Ohio State University Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · University of California, San Francisco (2) · University of Southern California (2) · University of Washington (2) · Abdullah Khan (1) · Alfred Chung, MD (1)
United States (80) · Germany (2) · Canada (1) · Denmark (1) · Italy (1)
Brenda Sandmaier (3) · Alfred Chung, MD (2) · Andrew Cowan (2) · Robert Orlowski (2) · Shaji K. Kumar, M.D. (2) · Shaji Kumar (2) · Shaji Kumar, M.D. (2) · Sikander Ailawadhi, M.D. (2) · Yvonne Efebera, MD (2) · Abdullah M Khan, MBBS, MSc (1) · Amir A Toor, MD (1) · Amrita Krishnan (1) · Amrita Krishnan, MD (1) · Angela Dispenzieri (1)
PMID 32499241, PMID 26943915, PMID 27410923, PMID 27702799, PMID 31248843, PMID 31558469, PMID 32268821, PMID 32299820, PMID 32478814, PMID 33095874, PMID 33720354, PMID 34156440, PMID 35175355, PMID 36898933, PMID 37300573, PMID 37414012, PMID 37611156, PMID 37812476, PMID 38698840, PMID 38797190, PMID 39863139, PMID 40198877, PMID 41043099
P30CA015083 (8), P30CA015704 (8), P30CA138292 (4), P01CA018029 (3), P01CA078902 (3), P30CA016672 (3), P30CA014089 (2), P30CA016058 (2), UM1CA186644 (2), N01CM00032 (1), N01CM00071 (1), N01CM00100 (1), N01CM62208 (1), P30CA006516 (1), P30CA012197 (1)